MINJUVI® (tafasitamab) provisionally approved by Therapeutic Goods Administration1 Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses2 Singapore, 28 June 2023: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that a new therapy to treat the most common type of non-Hodgkin lymphoma in